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Aims There are scant comparative data quantifying the risk of infective endocarditis (IE) and associated mortality in indi-
viduals with predisposing cardiac conditions.
...................................................................................................................................................................................................
Methods
and results
English hospital admissions for conditions associated with increased IE risk were followed for 5 years to quantify
subsequent IE admissions. The 5-year risk of IE or dying during an IE admission was calculated for each condition
and compared with the entire English population as a control. Infective endocarditis incidence in the English popula-
tion was 36.2/million/year. In comparison, patients with a previous history of IE had the highest risk of recurrence
or dying during an IE admission [odds ratio (OR) 266 and 215, respectively]. These risks were also high in patients
with prosthetic valves (OR 70 and 62) and previous valve repair (OR 77 and 60). Patients with congenital valve
anomalies (currently considered ‘moderate risk’) had similar levels of risk (OR 66 and 57) and risks in other ‘mod-
erate-risk’ conditions were not much lower. Congenital heart conditions (CHCs) repaired with prosthetic material
(currently considered ‘high risk’ for 6 months following surgery) had lower risk than all ‘moderate-risk’
conditions—even in the first 6 months. Infective endocarditis risk was also significant in patients with cardiovascular
implantable electronic devices.
...................................................................................................................................................................................................
Conclusion These data confirm the high IE risk of patients with a history of previous IE, valve replacement, or repair. However,
IE risk in some ‘moderate-risk’ patients was similar to that of several ‘high-risk’ conditions and higher than repaired
CHC. Guidelines for the risk stratification of conditions predisposing to IE may require re-evaluation.
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Introduction
Infective endocarditis (IE) is uncommon but has high morbidity and
mortality. Prevention and early detection are therefore important.1,2
International guideline committees have stratified individuals into
those at high, moderate, or low risk of developing or suffering a poor
outcome (see Supplementary material online, Table S1).3–5 Recent
estimates suggest there are >800 000 individuals at ‘high risk’ and 4.2–5.2
million with native valve disease at ‘moderate risk’ of developing IE in the
USA alone.6 The study most widely used by guideline committees to
stratify risk included little comparative data quantifying the risk of a poor
outcome,7 and there are no data to quantify the relative risks of develop-
ing IE or dying during an IE admission associated with different predispos-
ing cardiac conditions in a single large population-based cohort.
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The aim of this study was to identify individuals with different car-
diac risk factors for IE and quantify the relative 5-year risk of develop-
ing IE or dying during an IE admission (as a marker of poor outcome)
using data for all English hospital admissions between 2000 and 2013.
Methods
Data source
All patients admitted to English hospitals are assigned a unique National
Health Service (NHS) number and coded in the Hospital Episode
Statistics (HES) database according to age, gender, primary discharge
diagnosis [ICD-10 http://apps.who.int/classifications/apps/icd/icd10online
(1 November 2017)], or procedures performed [OPCS-4 http://systems.
digital.nhs.uk/data/clinicalcoding/codingstandards/opcs4 (1 November
2017)]. Patients who die during a hospital admission are recorded as
discharged dead. All others are recorded as discharged alive.8,9 NHS
Digital [http://content.digital.nhs.uk (1 November 2017)] provided an
anonymized, uniquely numbered data extract for the period January
2000–March 2013 that allowed linkage of all hospital admission records
for an individual but precluded access to identifiable patient data.
Risk cohorts
Within the data extract, ICD-10 and OPCS-4 codes were used to identify
individuals admitted to hospital between January 2000 and March 2008 with
diagnoses or cardiac procedures that might put them at risk of IE (see
Supplementary material online, Table S2) and were divided into four groups:
(A) ‘High risk’—conditions that place individuals at high risk of IE [as
defined by the current European Society for Cardiology (ESC)3 and
American Heart Association (AHA)5 guidelines].
(B) ‘Moderate risk’—conditions that place individuals at moderate risk (as
defined by the current ESC3 and AHA5 guidelines).
(C) ‘Unknown risk’—conditions where there is uncertainty, guideline dis-
agreement, or lack of data regarding the risk of IE.
(D) Reference—The English population in 2008.
Individuals were followed up within the HES database for a minimum
of 5 years (up to March 2013) to identify subsequent hospital admissions
with a primary discharge diagnosis of IE (ICD-10 code I33.0). A dis-
charged ‘dead’ outcome was used as a measure of poor outcome. All IE
hospital admissions in England and all IE admissions resulting in a dis-
charged ‘dead’ outcome were recorded for the reference group.
Analysis
Patients with IE are often transferred between specialists in the same hos-
pital or to another hospital for treatment. Previously described method-
ology was used to ensure single continuous episodes of IE were only
counted once.10 Readmission for IE relapse was distinguished from admis-
sion with a new IE episode. Although molecular phenotyping of the causa-
tive pathogen is generally required to distinguish between relapse and a
new infection,11 episodes of IE occurring >6 months after a previous epi-
sode are generally regarded by researchers and clinicians as a new infec-
tion.12–17 A ‘lockout period’ of 6 months was therefore used to define
any subsequent IE hospital admission as a new episode—any IE
readmission within 6 months was excluded. Other lockout periods were
also assessed (see Supplementary material online, Figure S1). Patients with
one condition, e.g. cyanotic congenital heart disease (CHD), who subse-
quently had a procedure performed, e.g. repair using prosthetic material,
were evaluated for up to 5 years as having cyanotic CHD. If the proce-
dure was performed after 5 years, they were separately evaluated for up
to 5 years as a patient with repaired CHD. If the repair happened during
the 5 years of cyanotic CHD follow-up, then they were analysed as having
cyanotic CHD up to the point of the procedure. After that, until 5 years
of evaluation as cyanotic CHD had elapsed, they were evaluated as if
both conditions were running concurrently (and then as CHD repair
only until 5 years had elapsed from the procedure).
The incidence data were expressed as (i) the number of individuals with
that condition (or in the reference population) admitted to hospital
with IE/million/year and (ii) the number of individuals admitted to hospital
with IE who died during that admission/million/year.
Preliminary analysis showed that the effects of predictor variables
upon IE-free survival were not additive or constant over time and there-
fore failed to satisfy the conditions for Cox’s (proportional hazards)
regression analysis (Cox proportional hazard assumption, P< 0.0001).18
One approach to address these problems is to include time as an interac-
tion term. However, the large number of risk groups would make the
model difficult to interpret. Therefore, logistic regression analysis was
used to calculate the likelihood [expressed as odds ratio (OR)] of differ-
ent groups developing IE or dying during an IE admission over the subse-
quent 5 years (compared with the reference group). This also allowed us
to correct for the effect of age and gender. The reference data were the
likelihood of anyone in the entire English population of 2008
(n= 51 815 853) developing IE or dying during an IE-admission over the
subsequent 5 years. The Kaplan–Meier survival curves were derived for
IE-free survival and survival free of death during an IE-admission to dem-
onstrate time-related change in risk. Five-year number needed to harm
figures were calculated19 and are shown in each Kaplan–Meir survival
graph legend (Figure 4). Statistical analyses were performed using R statisti-
cal software [version 3.0, https://www.r-project.org (1 November 2017)].
As a robustness check to our logistic model, we estimated directly the
standardized rates (using the English mid-year 2008 population,
Supplementary material online, Tables S3 and S4) using two different bias
correction methods (see Supplementary material online Tables S5 and
S6). See Supplementary material online for more information.
Results
Epidemiology of infective endocarditis
The incidence of IE in the English population (reference group) was
36.2 cases/million/year with an IE admission-related mortality of 6.3/
million/year (17.4%). More men developed IE (69%) and prevalence
was highest in the 8th decade (Figure 1).
There were 96 021 individuals at ‘high risk’ of IE, of whom 2385
(2.5%) were admitted to hospital with an IE diagnosis within 5 years
and 508 (21%) died during admission (Table 1). There were 265 436
‘moderate-risk’ individuals, of whom 3714 (1.4%) had an IE hospital
admission within 5 years and 943 (25%) died during admission
(Table 1). Although IE incidence was significantly lower in ‘moderate-
risk’ individuals than those at ‘high risk’ (P< 0.001), the incidence of IE
related death was significantly higher (P= 0.002). There were also
marked differences in the age and gender distribution of individuals
with different predisposing cardiac conditions (see Supplementary
material online, Figures S2–S4).
Incidence of infective endocarditis and
infective endocarditis-related death in
individuals with different cardiac risk factors
The incidence of IE and death during an IE admission for patients with
different predisposing cardiac conditions are shown in Table 1.
2 M.H. Thornhill et al.
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..Incidence was highest in those with a previous history of IE and in
those with prosthetic or repaired valves. It was also high in those
with congenital heart conditions (CHCs) with a shunt or conduit but
lower in those with cyanotic CHC (and considerably lower in those
with CHC repaired with prosthetic material). Indeed, incidence of IE
and death during an IE admission were higher in those with a history
of rheumatic fever or non-rheumatic valve disease (currently cate-
gorised ‘moderate risk’ by international guidelines)3,5 than in those
with cyanotic CHC or CHC repaired with prosthetic material.
Incidence of IE was higher in those with congenital valve anomalies
than those with cyanotic congenital heart disease although mortality
was lower.
Relative risk of developing infective
endocarditis or infective endocarditis -
related mortality
The 5-year risks of developing IE or dying during an IE admission with
different cardiac conditions are compared with the reference group
in Table 2 and Figure 2.
Previous IE conferred the highest risk of developing IE [OR 265.5,
95% confidence interval (CI) 244.2–288.2] or dying during an IE-
related hospital admission (OR 214.9, 95% CI 179.2–255.6). These
findings were independent of lockout period duration (see
Supplementary material online, Figure S1). These risks were also high
Figure 1 Incidence of infective endocarditis in England from January 2000 to March 2015. (A) Incidence of infective endocarditis admissions.
(B) Incidence of infective endocarditis admissions where the patient dies during the admission.
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..in those with prosthetic or repaired valves, or palliative shunts/con-
duits. Along with cyanotic CHC, these are all categorized as ‘high risk’
by current guidelines.3,5
For cyanotic CHC, the risk of IE (OR 55.4, 95% CI 45.6–66.6) was
similar to that for those with a history of rheumatic fever (OR 51.4,
95% CI 47.9–55.0), currently categorized ‘moderate risk’.3,5 However,
the risk of poor outcome (defined by death during IE admission) was
higher in cyanotic CHC (OR 133.6, 95% CI 68.8–231.7) than in those
with a history of rheumatic fever (OR 54.5, 95% CI 48.0–61.7).
The risk of IE or dying during an IE admission in patients with con-
genital valve anomalies (currently categorized ‘moderate risk’) was
similar to several ‘high-risk’ conditions (with overlapping CIs).
Moreover, patients with CHC repaired with prosthetic material (cur-
rently considered ‘high risk’ for the first 6 months after surgery)3,5
had a lower risk of IE (OR 18.3, 95% CI 11.8–26.8) or death during an
IE admission (OR 24.4, 95% CI 7.5–56.8) than all those currently con-
sidered at ‘moderate risk’ of IE.
In the ‘unknown-risk’ group, implanted pacemakers/cardioverters
[cardiovascular implantable electronic devices (CIEDs)] conferred a
small but significant risk of IE (OR 9.7, 95% CI 9.0–10.6) and IE-
related death (OR 10.1, 95% CI 8.6–11.7), while the risk of IE (but
not dying during an IE admission) was significant in patients with
hypertrophic cardiomyopathy (OR 32.8, 95% CI 23.3–44.6 and OR
4.0, 95% CI 0.2–17.5). Prosthetic hearts/ventricular assist devices
conferred a significant risk of IE, but the risk associated with a heart
transplant was insignificant. In both conditions, the number of IE-
related deaths was too small to calculate an OR.
The risk of IE or dying during an IE hospital admission was signifi-
cantly higher in men (OR 2.15, 95% CI 2.08–2.23, P< 0.0001 and OR
1.65, 95% CI 1.53–1.77, P< 0.001) than women and in these aged 70–
79 years (Table 2 and Figure 3).
Survival analysis for freedom from
infective endocarditis and death during
infective endocarditis admission
The 5-year Kaplan–Meier survival curves (Figure 4) show how risks
changed with time and demonstrate that (i) the risk of developing IE
or dying during IE admission in patients with shunts or conduits
increased dramatically after 4 years compared with other conditions
and (ii) these risks were consistently low in patients with CHC
repaired with prosthetic material (including during the first 6 months
after repair). Ten-year Kaplan–Meier curves are provided in
Supplementary material online, Figures S5–S7.
Discussion
Summary of findings
Our study of the English population quantifies the risks of developing
IE and dying during an IE admission (as a measure of poor outcome)
with different predisposing cardiac conditions. It confirms that these
risks are high in those with a history of previous IE or valve surgery
but demonstrate that risks in other patient groups may be under- or
....................................................................................................................................................................................................................
Table 1 Incidence of IE or IE admission-related death in different predisposing risk conditions
Condition Size of study
population (n)
IE admissions
in 5 years
Incidence of IE
(cases/million/year)
IE admission
deaths in 5 years
(% of IE admissions)
Incidence of IE
admission deaths
(deaths/million/year)
High risk
Previous IE 9388 674 14 359 138 (21%) 2940
Prosthetic valve replacement 52 746 1223 4637 288 (24%) 1092
Valve repair with prosthetic material 13 674 322 4710 62 (19%) 907
Unrepaired cyanotic CHC 12 028 114 1896 11 (10%) 183
CHC repaired with prosthetic material 6328 23 727 4 (17%) 126
CHC with palliative shunt or conduit 1857 29 3123 5 (17%) 539
Total—high risk 96 021 2385 4968 508 (21%) 1058
Moderate risk
Rheumatic fever 66 004 1005 3045 305 (30%) 924
Non-rheumatic valve disease 190 451 2602 2732 630 (24%) 662
Congenital valve anomalies 8981 107 2383 8 (8%) 178
Total—moderate risk 265 436 3714 2798 943 (25%) 711
Unknown risk
Heart transplant 993 1 201 0 (0%) 0
Prosthetic heart/VAD 69 2 5797 0 (0%) 0
Hypertrophic cardiomyopathy 4418 37 1675 1 (3%) 45
Implanted pacemaker/cardioverter 192 296 652 678 193 (30%) 201
Total—unknown risk 197 776 692 700 194 (28%) 196
Reference group
The population of England (2008) 51 815 853 9386 36.2 1652 (18%) 6.4
CHC, congenital heart condition; IE, infective endocarditis; VAD, ventricular assist device.
4 M.H. Thornhill et al.
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overestimated by current international guidelines. Some
reclassification may be appropriate in light of this evidence.
Specifically, the risks of developing IE or dying during IE-admission in
those with congenital valve anomalies (currently considered ‘moder-
ate risk’) were very similar (with overlapping CIs) to those for several
‘high-risk’ conditions (including patients with prosthetic heart valves,
valves repaired with prosthetic material or cyanotic CHC). Risks
were only slightly lower in other ‘moderate-risk’ conditions (history
of rheumatic fever or non-rheumatic valve disease) and considerably
higher than in patients with CHC repaired with prosthetic material.
Current guidelines only categorize individuals with CHC repaired
with prosthetic material as ‘high risk’ for the first 6 months after sur-
gery.3,5 However, our data showed that the 5-year risk of IE or death
during IE admission in these individuals was persistently lower than
for all other ‘high- or moderate-risk’ conditions. In contrast, these
risks (particularly dying during an IE admission) were markedly higher
in CHC patients who underwent shunt or conduit implantation and
increased further after 4 years. This suggests shunts and conduits
carry innate risk or are used in patients with conditions that place
them at particularly high risk.
The number of patients in the ‘unknown-risk’ group with heart
transplants or ventricular assist devices was small, limiting the precise
assessment of risk. However, although IE risk was significantly
increased in patients with hypertrophic cardiomyopathy, the risk of a
poor outcome was low. The risks of IE and dying during an IE
admission were small but significant in patients with CIEDs.
The high proportion of individuals with a previous history of IE
(21%), prosthetic (24%), or repaired heart valves (19%) who had a
....................................................................................................................................................................................................................
Table 2 Five-year risk of IE or dying during an admission with IE with different predisposing conditions, gender, and
age
Predisposing condition OR of developing
IE in 5 years
95% CI P-value OR of dying
during a hospital
admission with IE
95% CI P-value
High risk
Previous IE 265.5 244.2–288.2 <0.0001 214.9 179.2–255.6 <0.0001
Prosthetic valve replacement 70.1 65.8–74.7 <0.0001 62.0 54.4–70.4 <0.0001
Valve repair with prosthetic material 76.7 68.3–85.8 <0.0001 59.5 45.6–76.1 <0.001
Cyanotic CHC 55.4 45.6–66.6 <0.0001 133.6 68.8–231.7 <0.001
CHC repaired with prosthetic material 18.3 11.8–26.8 <0.0001 24.4 7.5–56.8 <0.001
CHC with palliative shunt or conduit 86.1 58.1–122.1 <0.0001 314.5 111.6–688.0 <0.001
Moderate risk
Rheumatic fever 51.4 47.9–55.0 <0.0001 54.5 48.0–61.7 <0.0001
Non-rheumatic valve disease 41.5 39.6–43.6 <0.0001 35.9 32.6–39.5 <0.0001
Congenital valve anomalies 66.4 55.4–80.1 <0.0001 56.7 25.8–106.0 <0.001
Unknown risk
Heart transplant 5.5 0.3–24.2 0.089 NC NC NC
Prosthetic heart/VAD 124.2 20.3–398.9 <0.0001 NC NC NC
Hypertrophic cardiomyopathy 32.8 23.3–44.6 <0.0001 4.0 0.2–17.5 0.17
Implanted pacemaker/cardioverter 9.7 9.0–10.6 <0.0001 10.1 8.6–11.7 <0.001
Reference group
The population of England (2008) 1.0 1.0
Sex
Female (reference group) 1.00 1.00
Male 2.15 2.08–2.23 <0.0001 1.65 1.53–1.77 <0.001
Age
0–9 years 0.93 0.87–1.0 0.047 0.04 0.02–0.07 <0.001
10–19 years 0.24 0.21–0.27 <0.0001 0.01 0.00–0.03 <0.001
20–29 years 0.30 0.27–0.33 <0.0001 0.26 0.2–0.33 <0.001
30–39 years 0.68 0.63–0.73 <0.0001 0.55 0.46–0.66 <0.001
40–49 years 0.84 0.79–0.90 <0.0001 0.39 0.32–0.47 <0.001
50–59 years (reference group) 1.00 1.00
60–69 years 1.55 1.46–1.64 <0.0001 1.8 1.56–2.06 <0.001
70–79 years 1.96 1.85–2.07 <0.0001 3.28 2.90–3.72 <0.001
80–89 years 1.61 1.51–1.73 <0.0001 2.95 2.57–3.39 <0.001
90þ years 0.71 0.58–0.86 <0.001 0.94 0.62–1.37 0.76
P-values compare the odds ratio for each condition, gender, or age with the relevant reference group.
CHC, congenital heart condition; IE, infective endocarditis; VAD, ventricular assist device, NC, not calculable.
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..poor outcome and died during an IE admission is not surprising, and
most guidelines recognize such individuals as ‘high risk’. The significant
number of individuals with CIEDs who develop IE and die (30%),
however, has only recently been highlighted.20,21 Moreover, the high
proportions with a previous history of rheumatic fever (30%) or non-
rheumatic valve disease (24%) who have a poor outcome and die are
unexpected and concerning. Several factors could explain this. Not
being labelled ‘high risk’ could result in a lower index of suspicion for
the early diagnosis of IE and an inappropriate sense that treatment
need not be as intense as for those labelled ‘high risk’, leading to
delayed diagnosis, less effective treatment, and worse outcomes. It is
also possible that using hospital admission data to identify ‘moderate-
risk’ individuals, we selected those with more severe disease or co-
morbidities that could increase their risk of IE (including health care-
related IE).
Research in context
The incidence of IE (36.2 cases/million/year) in the English reference
population agrees closely with the incidence of IE in the French popu-
lation for the same year (33.8 cases/million/year)22 and a recent
crude estimate (15–116 cases/million/year) based on data from 10
countries.23 Moreover, we identified 361 457 individuals at increased
risk of IE [‘high risk’ 96 021 (27%), ‘moderate risk’ 265 436 (73%)] in
keeping with the US studies.6
Consistent with the current ESC and ACC/AHA guidelines,3,5 the
5-year risk of IE or a poor outcome (death during an IE admission)
was high in patients with a previous history of IE, prosthetic or
repaired heart valves, cyanotic CHC, or CHC repaired with a shunt
or conduit. Although we found a very high incidence of IE in patients
with a previous history of IE (14 359 cases/million/year or 1.44%), this
was lower than some estimates from smaller, single-condition
Figure 2 Five-year risk (odds) of developing infective endocarditis or dying during an infective endocarditis admission in different cardiac condi-
tions. *Excluding recurrent infective endocarditis within 180 days of the original episode.
6 M.H. Thornhill et al.
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.studies, where the criteria that we used to exclude relapse were not
always observed (2–22%).11 Our incidence of prosthetic valve IE was
also high (4637 cases/million/year or 0.46%) and close to that of sev-
eral smaller studies (0.1–2.3%)24 and our incidence of IE for unre-
paired cyanotic CHC (1896 cases/million/year or 0.19%) closely
matched a study of 1347 patients with ventricular septal defect (1450
cases/million/year [95% CI 990–2050 cases/million/year]).25
We observed an elevated risk of IE (but low risk of death during IE
admission) in patients with hypertrophic cardiomyopathy. These find-
ings are consistent with previous data and suggest that patients with
hypertrophic cardiomyopathy generally have better outcomes than
with other conditions predisposing to IE.26 The number of patients
with CIEDs is increasing rapidly and our study supports recent data,
suggesting a small but significant risk of IE in this group.27 Indeed, our
data indicate a risk of IE or dying during IE admission that is10 times
greater than the general population.
Consistent with other studies,24 the 5-year risk of men developing
IE was more than twice that of women in this study, but there are
few data concerning the risk of a poor outcome, which we found was
1.65 times higher in men. The increasing risks of IE with age (peaking
in the 8th decade) are well recognized but an extra peak in risk of IE
in children aged <10 years (principally due to CHC) was also noted.
However, there was no associated increase in the risk of death during
IE-admission, suggesting that children generally have better outcomes
from IE than older patients.
Strengths and weaknesses
Hospital Episode Statistics ICD-10 coding data, rather than individual
patient medical records, were used to identify episodes of IE.28
However, HES codes the discharge diagnosis of patients, which in the
case of IE is based on Duke criteria in the UK, and therefore on the
results of echocardiography and blood cultures (even though these
data items were not directly collected). Despite this, National coding
data does have limitations. Nonetheless, a recent study showed that
Duke criteria positive IE cases were identified with 95% sensitivity
(95% CI 86–99%) and 100% specificity (95% CI 100–100%) using sim-
ilar methodology.29 Our data were collected independently by
trained and accredited coding personnel and should therefore be
free of selection bias. Moreover, the size of the data set and the inde-
pendence and consistency of the coding process minimize the likeli-
hood of systematic errors.
A further limitation is that some of the categories used (such as
non-rheumatic or congenital valve disease) were broad and could
encompass conditions with widely differing risk of IE. Nonetheless,
they reflect the categories currently used by international guideline
committees.3,5
Figure 3 Five-year risk (odds) of developing infective endocarditis or dying during an infective endocarditis admission stratified by age and gender.
Gender reference population = female, age reference population = 50–59 years.
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Figure 4 The Kaplan–Meier survival curves for infective endocarditis-free survival (A–C) and death during an infective endocarditis admission-free
survival (D–F), for each condition. These demonstrate the curves for patients with ‘high risk’ (A and D), ‘moderate risk’ (B and E) and ‘unknown risk’
(C and F) as defined in the ‘Methods’ and by the European Society for Cardiology and American Heart Association (see Supplementary material
online, Table S1). For scale and ease of comparison, the previous infective endocarditis population (the highest risk condition) is included in each
panel. **Infective endocarditis reoccurrence within 180 days of the original episode has been excluded in the group with previous infective endocar-
ditis. CHC, congenital heart condition; VAD, ventricular assist device; NNH, 5-year number needed to harm; NC, not calculable.
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Comorbidity data were not available, and we were unable to
account for the effect of comorbidities, e.g. immunosuppression, dia-
betes or renal disease, on the risk of IE. Similarly, we were unable to
evaluate the impact of different causal organisms on IE outcome.
Using population data, a patient with one condition, e.g. cyanotic
CHD, could undergo a procedure (e.g. repair with prosthetic mate-
rial) that alters their risk status (in this case lowers it) for part of the
5-year follow-up period. In the context of the much larger number of
individuals with no change, the number, duration, and effect of any
change in status was very small. Nonetheless, such events could mar-
ginally inflate or deflate the true risk associated with any condition. In
addition, the data set only recorded deaths during an IE hospital
admission. Although this provides a simple and effective measure for
quantifying poor outcome, it does not capture deaths following dis-
charge from hospital and therefore underestimates the true mortality
of IE.
Finally, there was a gradual increase in IE incidence during the study
that accelerated in 2008.8 Although reference population data and
use of ORs help to correct for changes in the relative risk of IE caused
by background incidence changes, we cannot exclude the possibility
that some risks might have changed during the study.
There were differences in the age and gender distribution of indi-
viduals with different conditions, e.g. those with CHC had a lower
age profile than those with acquired conditions (see Supplementary
material online, Figures S2–S4). Use of logistic regression to calculate
the odds of developing IE or dying during IE admission allowed us to
correct for the age and gender differences. As a result, the relative
size of the OR does not always reflect the incidence data for the
same condition. Generally, the OR was higher for CHC and lower
for acquired conditions than the incidence figures might suggest.
Conclusions
Data on the risk of developing or dying from IE after different cardio-
logical diagnoses and procedures is important for prognostication
and patient risk–benefit advice. Risk stratification guidelines are also
important in raising the diagnostic threshold of suspicion for IE in
those at risk and guiding treatment and prevention strategies includ-
ing advice on oral hygiene, dental care, avoidance of intravenous drug
use, body piercings, and so on.
This study quantifies IE risk and its consequences from all causes
and confirms the high-risk status of individuals with a previous history
of IE or valve surgery. It also confirmed the high-risk status of most
other conditions considered ‘high risk’ by international guideline
committees. The risk of IE or dying during an IE admission for patients
with congenital valve anomalies (currently categorized ‘moderate
risk’) was, however, similar to several ‘high-risk’ conditions and the
risk with other ‘moderate-risk’ conditions was only a little lower. In
contrast, the risks associated with CHC repaired with prosthetic
material (currently categorized ‘high risk’ for the first 6 months) were
lower than for all ‘moderate-risk’ conditions. Our data also showed a
highly significant 10-fold increase in the risks of IE or death from IE
in individuals with CIEDs. These findings suggest the need to consider
re-evaluating IE risk stratification of cardiac conditions and provide
valuable data for international guideline committees to take into
consideration in formulating recommendations for IE risk assessment,
prevention, and management.
Supplementary material
Supplementary material is available at European Heart Journal online.
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